{"id":544324,"date":"2016-06-08T15:52:52","date_gmt":"2016-06-08T13:52:52","guid":{"rendered":"https:\/\/hpsitaly.healthcare\/?p=544324"},"modified":"2022-03-26T13:19:39","modified_gmt":"2022-03-26T12:19:39","slug":"carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante","status":"publish","type":"post","link":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/","title":{"rendered":"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante"},"content":{"rendered":"<p><strong>Clinical Brief Anno II, N. 1, Maggio 2016<br \/>\nISSN 2499-7706<\/strong><\/p>\n<p><strong>Indice<\/strong><\/p>\n<ul>\n<li><strong>Introduzione<\/strong><\/li>\n<li>Bibliografia<\/li>\n<li><strong>Malattia viscerale<br \/>\n<\/strong>E Bellini<br \/>\n<em>AOU Citt\u00e0 della Salute e della Scienza di Torino<\/em><\/p>\n<ul>\n<li>Situazione clinica iniziale e terapia adiuvante<\/li>\n<li>Approccio terapeutico alla malattia metastatica<\/li>\n<li>Considerazioni cliniche<\/li>\n<li>Scheda riepilogativa<\/li>\n<li>Bibliografia<\/li>\n<\/ul>\n<\/li>\n<li><strong>Malattia ossea<\/strong><br \/>\nD Galanti, MR Valerio, L Terruso, V Gristina, A Marchese, M Fricano, S Latteri, MT Catarella<br \/>\n<em>Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche-Oncologia Medica, Universit\u00e0 di Palermo, Palermo<\/em><\/p>\n<ul>\n<li>Situazione clinica iniziale e terapia adiuvante<\/li>\n<li>Approccio terapeutico alla malattia metastatica<\/li>\n<li>Considerazioni cliniche<\/li>\n<li>Scheda riepilogativa<\/li>\n<li>Bibliografia<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Brief Anno II, N. 1, Maggio 2016 ISSN 2499-7706 <a href=\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":64199,"featured_media":545295,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1001],"tags":[],"class_list":["post-544324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-brief-eng"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante - HPS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante - HPS\" \/>\n<meta property=\"og:description\" content=\"Clinical Brief Anno II, N. 1, Maggio 2016 ISSN 2499-7706 [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/\" \/>\n<meta property=\"og:site_name\" content=\"HPS\" \/>\n<meta property=\"article:published_time\" content=\"2016-06-08T13:52:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-26T12:19:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"653\" \/>\n\t<meta property=\"og:image:height\" content=\"912\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Eleonora Zaghis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eleonora Zaghis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/\",\"url\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/\",\"name\":\"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante - HPS\",\"isPartOf\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png\",\"datePublished\":\"2016-06-08T13:52:52+00:00\",\"dateModified\":\"2022-03-26T12:19:39+00:00\",\"author\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd\"},\"breadcrumb\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#primaryimage\",\"url\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png\",\"contentUrl\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png\",\"width\":653,\"height\":912,\"caption\":\"CARCINOMA MAMMARIO METASTATICO HR+HER2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hpsitaly.healthcare\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#website\",\"url\":\"https:\/\/hpsitaly.healthcare\/\",\"name\":\"HPS\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hpsitaly.healthcare\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd\",\"name\":\"Eleonora Zaghis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g\",\"caption\":\"Eleonora Zaghis\"},\"url\":\"https:\/\/hpsitaly.healthcare\/en\/author\/eleonora-zaghis\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante - HPS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/","og_locale":"en_US","og_type":"article","og_title":"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante - HPS","og_description":"Clinical Brief Anno II, N. 1, Maggio 2016 ISSN 2499-7706 [...]","og_url":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/","og_site_name":"HPS","article_published_time":"2016-06-08T13:52:52+00:00","article_modified_time":"2022-03-26T12:19:39+00:00","og_image":[{"width":653,"height":912,"url":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png","type":"image\/png"}],"author":"Eleonora Zaghis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Eleonora Zaghis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/","url":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/","name":"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante - HPS","isPartOf":{"@id":"https:\/\/hpsitaly.healthcare\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#primaryimage"},"image":{"@id":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#primaryimage"},"thumbnailUrl":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png","datePublished":"2016-06-08T13:52:52+00:00","dateModified":"2022-03-26T12:19:39+00:00","author":{"@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd"},"breadcrumb":{"@id":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#primaryimage","url":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png","contentUrl":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2016\/06\/CARCINOMA-MAMMARIO-METASTATICO-HRHER2.png","width":653,"height":912,"caption":"CARCINOMA MAMMARIO METASTATICO HR+HER2"},{"@type":"BreadcrumbList","@id":"https:\/\/hpsitaly.healthcare\/en\/clinical-brief-eng\/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hpsitaly.healthcare\/en\/"},{"@type":"ListItem","position":2,"name":"Carcinoma mammario metastatico HR+\/HER2\u2013: trattamento di prima linea con everolimus in pazienti in ricaduta durante terapia adiuvante"}]},{"@type":"WebSite","@id":"https:\/\/hpsitaly.healthcare\/#website","url":"https:\/\/hpsitaly.healthcare\/","name":"HPS","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hpsitaly.healthcare\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd","name":"Eleonora Zaghis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g","caption":"Eleonora Zaghis"},"url":"https:\/\/hpsitaly.healthcare\/en\/author\/eleonora-zaghis\/"}]}},"_links":{"self":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/users\/64199"}],"replies":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/comments?post=544324"}],"version-history":[{"count":3,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544324\/revisions"}],"predecessor-version":[{"id":545298,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544324\/revisions\/545298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/media\/545295"}],"wp:attachment":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/media?parent=544324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/categories?post=544324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/tags?post=544324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}